CHMFL-ABL-039

• UNSPSC Description:

  CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/chmfl-abl-039.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CN=C(NC(C2CC2)=O)C=C1)CC3=CC=C(NC(C4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4)=O)C=C3

• Molecular Weight:

  594.63

• References & Citations:

  [1]Wu J, et al. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia(CML). Cancer Biol Ther. 2019;20(6):877-885.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2304344-56-5